Trial Profile
A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Faricimab (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms BOULEVARD
- Sponsors Roche
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 26 Jul 2018 According to a Roche media release, data were presented at 36th Annual Meeting of the American Society of Retina Specialists (ASRS).
- 02 Mar 2018 Status changed from active, no longer recruiting to completed.